TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00913250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serum containing Avonex
Description: 60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serum Free Avonex
Description: 60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
Study: NCT03558022

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Pills
Description: 7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pills
Description: 7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
Study: NCT02923089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muffin: 25g available carbohydrate from small green lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muffin: 25g available carbohydrate from split red lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat muffin
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soup: 25g available carbohydrate from small green lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soup: 25g available carbohydrate from split red lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potato soup
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chili: 25g available carbohydrate from small green lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chili: 25g available carbohydrate from split red lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice chili
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study: NCT02653300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
Study: NCT00204971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral glutamine powder
Description: nutritional supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study: NCT00328822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00626210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: 100-400 mg daily for 4 weeks
Study: NCT04047693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose dense MVAC with pegylated GCSF
Description: Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
Study: NCT03417518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Inhalant Product
Description: General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
Study: NCT03558256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication
Description: Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
Study: NCT00446238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT enhanced with physical illness narrative, family education, and social skills components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Community Care Treatment
Description: Treatment as usual for depression and related symptoms provided within the community.
Study: NCT03651583

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kiko exercises-combines breathing and movement
Study: NCT04460014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task intervention
Description: Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo
Description: Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
Study: NCT01306422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hoodia gordonii purified extract (H.g.PE)
Description: H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt drink
Description: Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt drink
Description: Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt drink
Description: Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hoodia gordonii purified extract (H.g.PE)
Description: H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hoodia gordonii purified extract (H.g.PE)
Description: H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
Study: NCT03788395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler plus Turbo+
Description: Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbohaler without Turbo+
Description: Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
Study: NCT01605981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107
Study: NCT04194853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback
Description: Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Isometric exercises
Description: In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
Study: NCT00108069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate
Description: oral dose 120 mg twice a day, every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate
Description: oral dose 120 mg twice a day, every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
Study: NCT01983397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Description: The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
Study: NCT01612143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: setrobuvir
Description: 200 mg capsule formulation, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: setrobuvir
Description: 200 mg capsule formulation, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: 200 mg tablet formulation, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: 200 mg tablet formulation, single oral dose
Study: NCT00953719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 36 mm ceramic head on a ceramic acetabular liner
Description: Total hip replacement with a 36 mm ceramic head on a ceramic liner

Intervention type: DEVICE
Group type: OTHER
Intervention: 28 mm ceramic head on a polyethylene acetabular liner
Description: Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
Study: NCT03248934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Administered Diagnostic Exam
Description: Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinician-Performed Diagnostic Exam
Description: A clinician-performed diagnostic exam will be completed on the patients.
Study: NCT01182766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate with brief behavioral enhancement therapy
Description: high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with brief behavioral enhancement therapy
Description: placebo
Study: NCT03027557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg Tablet
Description: Participants in one arm will receive 30 mg cinacalcet each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Inj 60 mg/ml
Description: Participants in two arms will receive 60 mg Denosumab biannually.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Inj 60 mg/ml
Description: Participants in two arms will receive 60 mg Denosumab biannually.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Participants in two arms will receive one placebo-tablet each day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Participants in two arms will receive one placebo-tablet each day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection (Placebo)
Description: Participants in one arm will receive saline injections as placebo for denosumab.
Study: NCT01478360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 (secukinumab)
Description: Secukinumab intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous injection
Study: NCT01812889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOL-463 Vaginal ovule
Description: TOL-463 Vaginal Ovule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOL-463 Vaginal ovule
Description: TOL-463 Vaginal Ovule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOL-463 Vaginal gel
Description: TOL-463 Vaginal Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOL-463 Vaginal gel
Description: TOL-463 Vaginal Gel
Study: NCT03123250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquablation
Description: The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
Study: NCT00932685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.5mg/kg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Game Boy
Description: Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
Study: NCT02033603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30mls of 0.5% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30mls of 0.5% ropivacaine
Study: NCT01205997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo(distilled water)
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Study: NCT04154904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
Study: NCT00753506

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artemisinin
Description: 100 mg of artemisinin twice per day for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Identical looking placebo capsule
Description: Identical looking placebo twice per day for 10 weeks
Study: NCT01840241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT03193502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban
Study: NCT04605172

Intervention type: OTHER
Intervention: hospitalization for premature birth
Description: Number of inborn and outborn infants prematurely born during a specific period of time

Intervention type: OTHER
Intervention: hospitalization for premature birth
Description: Number of inborn and outborn infants prematurely born during a specific period of time
Study: NCT01982097

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY 43-9006)
Description: The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
Study: NCT03906448

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTFields with adjuvant temozolomide
Description: Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
Study: NCT01205997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulphate
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Study: NCT03967782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON
Description: Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX-MEAL
Description: Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEAL-EX
Description: . condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study: NCT03818087

Intervention type: BEHAVIORAL
Intervention: Observational cohort
Description: Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
Study: NCT01609751

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult
Description: 62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
Study: NCT03836755

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metacos
Description: Evaluation of stability of implant by RSA technique